Education
About Us
Working with TipRanks
Follow Us
Citius Oncology, Inc. (CTOR)
:CTOR
CTOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $49.00
Previous CloseN/A
Volume120.49K
Average Volume (3M)136.21K
Market Cap
$47.58M
Enterprise Value$103.26M
Total Cash (Recent Filing)$289.18K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.47
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding71,552,400
10 Day Avg. Volume305,132
30 Day Avg. Volume136,209
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.15
Forecast
1Y Price Target
$3.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst initiates coverage of Citius Oncology with a Buy rating and a price target of $3.00, emphasizing the potential profitability and market expansion of Lymphir.
Growth OpportunitiesCitius Oncology plans to expand Lymphir's indications to peripheral T cell lymphoma and broader immune oncology, presenting additional growth opportunities.
Market OpportunityLymphir is on track to launch in the CTCL market with minimal direct competition, potentially gaining rapid market share.
Bears Say
CompetitionLymphir targets the IV-targeted therapy segment of the CTCL market, which typically follows progression on oral systemics and chemotherapies, potentially facing established competition.
Market AccessCitius Oncology is working with payers and healthcare providers to secure reimbursement pathways, indicating potential challenges in gaining market access.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTOR FAQ
What was Citius Oncology, Inc.’s price range in the past 12 months?
Citius Oncology, Inc. lowest stock price was $0.55 and its highest was $49.00 in the past 12 months.
What is Citius Oncology, Inc.’s market cap?
Citius Oncology, Inc.’s market cap is $47.58M.
When is Citius Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Citius Oncology, Inc.’s earnings last quarter?
Citius Oncology, Inc. released its earnings results on Dec 27, 2024. The company reported -$0.306 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.226.
Is Citius Oncology, Inc. overvalued?
According to Wall Street analysts Citius Oncology, Inc.’s price is currently Undervalued.
Does Citius Oncology, Inc. pay dividends?
Citius Oncology, Inc. does not currently pay dividends.
What is Citius Oncology, Inc.’s EPS estimate?
Citius Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Citius Oncology, Inc. have?
Citius Oncology, Inc. has 71,552,400 shares outstanding.
What happened to Citius Oncology, Inc.’s price movement after its last earnings report?
Citius Oncology, Inc. reported an EPS of -$0.306 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -5.6%.
Which hedge fund is a major shareholder of Citius Oncology, Inc.?
Currently, no hedge funds are holding shares in CTOR
---
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (354.55% Upside)
$3.00 (354.55% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.98%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
85.87%
Trailing 12-Months
Company Description
Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
---
CTOR Stock 12 Month Forecast
Average Price Target
$3.00
▲(354.55% Upside)
Technical Analysis
Best Analysts Covering CTOR
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-40.15%
reiterated a buy rating 3 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.15% per trade.
---